Newly Diagnosed Glioblastoma in Patients Older than 70 with Poor Functional Status and MGMT Promoter Methylation
This protocol covers the treatment of newly diagnosed glioblastoma in patients over age 70 who present with poor functional status and confirmed MGMT promoter methylation — a clinically distinct situation in which standard approaches are modified based on these specific patient characteristics.
Clinical Scenario
Age older than 70 years is a key factor shaping treatment selection in this population. Combined with poor functional status and the presence of MGMT promoter methylation, these variables — along with individual care goals — directly determine which pathway is appropriate following maximal safe resection.
Treatment Considerations
Clinical trial eligibility is assessed as a first step. For patients with confirmed MGMT promoter methylation, a chemotherapy-based approach is among the options considered. The full decision pathway — including eligibility criteria, specific regimen options, and sequencing — is available in the complete protocol.
References
DOI: 10.1093/neuonc/noaf177
Treatment decisions for glioblastoma after maximal safe resection depend on age, functional status, MGMT status, and patient care goals (Figure 8).
Treatment regimens for newly diagnosed glioblastoma patients older than 65–70 years involve standard radiochemotherapy but shortened regimens for frailer patients may include hypofractionated radiation (eg, 40 Gy in 15 fractions) with temozolomide, hypofractionated radiation alone for patients with MGMT unmethylated glioblastoma, or temozolomide alone for patients with MGMT methylated glioblastoma.
View source ↗